Organization | AryoGen Pharmed Co.

AryoGen Pharmed Co. Report issue

For profit Phase 1 Phase 3

Founded: Tehran Iran (Islamic Republic of) (2009)

Organization Overview

First Clinical Trial

2016

NCT03425656

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

AryoGen Pharmed Co.

Active Ingredients

Drugs in Phase 3 Trials (11)

bevacizumab (avastin) (1 trial)

calcium (1 trial)

coagulation factor viia (recombinant) (NovoSevenRT) (2 trials)

denosumab (prolia) (1 trial)

docetaxel (taxotere) (1 trial)

eptacog (Novoseven) (1 trial)

fluorouracil (efudex) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

trastuzumab (herceptin) (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 1 Trials (1)

etanercept (enbrel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 3)

Factor VII Deficiency (Phase 3)

Hemophilia A (Phase 3)

Neoplasms (Phase 3)

Osteoporosis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial APIs: 12